Lynparza regulatory submission granted Priority Review in the US for HRR-mutated metastatic castration-resistant prostate cancer
20 January 2020 07:00 GMT Lynparza regulatory submission granted Priority Review in the USfor HRR-mutated metastatic castration-resistant prostate cancer Submission based on PROfound, the first positive Phase III trial testinga targeted treatment in biomarker-selected prostate cancer patients AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that a supplemental New Drug Application for Lynparza (olaparib) has been accepted and granted Priority Review in the US for patients with metastatic